Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma
Stephen M. Ansell(Mayo Clinic), David J. Straus(Memorial Sloan Kettering Cancer Center), Cassie Dong(The Christie NHS Foundation Trust), Andrea Gallamini(Centre Antoine Lacassagne), Kerry J. Savage(Spinal Cord Injury BC), Joseph M. Connors, Monika Długosz‐Danecka(National Institute of Oncology), Jonathan W. Friedberg(University of Rochester), Keenan Fenton(The Christie NHS Foundation Trust), Radhakrishnan Ramchandren(The Christie NHS Foundation Trust), Markus Puhlmann(The Christie NHS Foundation Trust), Ranjana H. Advani(Stanford Medicine), Piotr Smolewski(Medical University of Lodz), Andrew M. Evens(Rutgers, The State University of New Jersey), Martin Hutchings(University of Copenhagen), Hyeon‐Seok Eom(National Cancer Center), Nancy L. Bartlett(Washington University in St. Louis), Won-Seog Kim(Samsung Medical Center), Jeremy S. Abramson(Massachusetts General Hospital), Frank Campana(AVEO Oncology (United States)), John Radford(Manchester Academic Health Science Centre)
Cited by 342
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k